MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/gastro/goag099

Медицинская библиотека · Gastroenterology report · 2026

Mitochondrial fitness in circulating T cells predicts neoadjuvant therapy response in locally advanced colorectal cancer.

Huang Shishi, Fu Yang, Bai Fan, Cai Runkai, Zhang Jianwei, Qin Ge, Wu Zehua, Wu You, Zhan Weixiang, Qi Sifan, Deng Yanhong

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Traditional immunophenotyping based on cell counts has limited value in predicting neoadjuvant treatment outcomes for locally advanced colorectal cancer (LACRC). Because mitochondrial fitness is an essential factor in T-cell function, we hypothesized that the pretreatment metabolic profile of circulating T cells could predict therapeutic response. This study aimed to develop a novel pretreatment assessment system based on peripheral blood immunometabolic parameters.

METHODS

Baseline peripheral blood samples were prospectively collected from 72 patients with LACRC enrolled in the OPTICAL2 phase II clinical trial (NCT05571644), which compared neoadjuvant mFOLFOXIRI plus cadonilimab versus mFOLFOXIRI or mFOLFOX6. Multicolor flow cytometry was used to analyze the immunophenotype and mitochondrial characteristics of circulating T-cell subsets. A composite index, named Tscore, was constructed by using multivariate logistic regression. This model integrated five parameters: the CD4/CD8 ratio, mitochondrial mass of CD4⁺ and CD8⁺ central memory T cells and those of effector memory T cells.

RESULTS

Patients achieving pathological complete response showed higher T-cell mitochondrial mass and lower levels of low membrane potential than non-responders. The baseline Tscore predicted pathological complete response (pCR) with an area under the curve (AUC) of 0.976 (95% CI, 0.927-1.000; P < 0.001) in the immunochemotherapy group and 0.861 (95% CI, 0.736-0.986; P < 0.001) in the chemotherapy-alone group. In a small exploratory external validation (n = 25, 3 pCR events; post hoc power = 41.8%), the model yielded an AUC of 0.848. An R-based calculator was developed to estimate individual pCR probabilities for different neoadjuvant regimens.

CONCLUSIONS

Tscore is a noninvasive biomarker for predicting neoadjuvant therapy response in LACRC. These findings highlight the importance of pretreatment T-cell metabolic characteristics and provide a potential tool for individualized response assessment.

Для цитирования: Huang Shishi, Fu Yang, Bai Fan, Cai Runkai, Zhang Jianwei, Qin Ge, Wu Zehua, Wu You, Zhan Weixiang, Qi Sifan, Deng Yanhong. Mitochondrial fitness in circulating T cells predicts neoadjuvant therapy response in locally advanced colorectal cancer.. Gastroenterology report. 2026. DOI: 10.1093/gastro/goag099.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.